Explore the latest in clinical pharmacy and pharmacology, including topics in drug safety, development, pharmacogenetics, and pharmacoeconomics.
This Medical Letter compares a newly approved fixed-dose combination pill comprising the sodium-glucose cotransporter 2 inhibitor empagliflozin, the dipeptidyl peptidase-4 inhibitor linagliptin, and extended-release metformin, with available formulations of each of the pill’s individual components for oral treatment of type 2 diabetes in adults.
This review summarizes a report from the National Academies of Sciences, Engineering, and Medicine on the clinical utility of compounded bioidentical hormone therapy drug products.
This cross-sectional study examines the health characteristics of individuals who use mail-order pharmacies.
This cross-sectional study assesses potential opportunities for genotype-guided prescribing in pediatric populations among multiple health systems by examining the prevalence of prescriptions for each drug with the highest level of evidence and estimating the prevalence of potentially actionable prescribing decisions.
This cross-sectional study examines whether higher global symptom scores are associated with use of more medications and assesses associations between specific symptoms and medications among children with severe neurological impairment.
This cross-sectional study uses data from the IBM MarketScan Commercial Database to examine the association between increases in wholesale list prices of branded medications and amounts paid by patients and insurers for the same drugs.
This cohort study uses data from the National Health and Nutrition Examination Surveys to evaluate whether benzodiazepine use, with or without opioid use, is associated with increased all-cause mortality relative to the use of low-risk antidepressants.
This cohort study assesses the risk of second primary cancers in patients with primary melanoma before (2005-2010) and after (2011-2016) the introduction and approval of immune checkpoint inhibitors.
This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks’ gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo.
This Viewpoint proposes that a polypill combination of a β-blocker, renin angiotensin inhibitor, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor might be the most efficient way to deliver guideline-directed HFrEF therapy, and proposes a research roadmap to design and evaluate the pill and implementation strategies for getting it to patients.
This randomized clinical trial investigates whether routine CYP2D6 and CYP2C19 genotyping affects the persistence of antipsychotic drug treatment among adults with schizophrenia.
This randomized clinical trial examines the impact of delivering SLCO1B1 pharmacogenetic results to physicians on low-density lipoprotein cholesterol levels and concordance with prescribing guidelines for statin safety and effectiveness.
A 27-year-old woman with a history of heroin use presented with syncope but denied chest pain, shortness of breath, palpitations, or recent illicit drug use. Results of imaging tests were unremarkable, and electrocardiography was ordered. What would you do next?
This study uses IBM MarketScan database data to describe trends in zolpidem and low-dose trazodone dispensing among adults with employer-sponsored insurance or Medicare supplemental plans between 2011 and 2018, before and after a 2017 clinical practice guideline discouraged trazodone use for insomnia.
This randomized clinical trial examines the association of use of long-acting injectable antipsychotics for patients with early-phase schizophrenia with delayed time to hospitalization.
This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: